The FDA approved a supplement to abbreviated new drug application ANDA 075576 for omeprazole, held by Dr Reddy's Laboratories, on 27 August 2026. An abbreviated application is the route by which a generic version of an already-approved medicine reaches the market, and a supplement amends an existing authorisation rather than creating a new product.
The public record carries the application number, the holder and the drug name. It does not describe what changed, so this cannot be reported as a label change, a new indication, a restriction or a safety communication. It is an administrative approval affecting one manufacturer's generic omeprazole in the United States.
The Indian interest is the holder rather than the action. Dr Reddy's is an Indian manufacturer supplying the US generic market, and actions on applications of this kind are the machinery by which manufacturing sites, presentations and pack sizes change. None of that alters Indian availability or labelling, which follow CDSCO.
The clinically useful reminder attached to any omeprazole news is deprescribing. Long-term proton pump inhibitor use accumulates by inertia more than by decision: started for a self-limiting indication, continued indefinitely, and rarely reviewed. A regulatory notice about omeprazole is as good a prompt as any to check who on your list is still taking one and why.
- Nothing in this action changes omeprazole dosing, indications or safety monitoring
- Use it as a prompt to review long-term proton pump inhibitor prescriptions and record an indication for each
- Step down or stop where the original indication was self-limiting, warning patients about rebound acid symptoms for a week or two
- Continue without apology where there is a real indication: Barrett's oesophagus, previous ulcer bleeding, or ongoing NSAID use with risk factors
- Remember FDA actions do not govern Indian availability, which follows CDSCO
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free